Aleglitazar

Aleglitazar
Identifiers
CAS number 475479-34-6
PubChem 10274777
ChemSpider 8450255 Y
DrugBank DB08483
KEGG D08845 Y
ChEMBL CHEMBL519504 Y
Jmol-3D images Image 1
Image 2
Properties
Molecular formula C24H23NO5S
Molar mass 437.50812
 Y (verify) (what is: Y/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which is being developed by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is currently in phase II clinical trials.[2]

References

  1. ^ "Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar". United States Adopted Names. American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/aleglitazar.pdf. Retrieved 2008-08-17. 
  2. ^ ClinicalTrials.gov. "A Study of Aleglitazar in Patients With Type 2 Diabetes". United States National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00388518?cntry1=EU%3ARO&rank=50. Retrieved 2008-03-19.